Login to Your Account

Galapagos Acquires Cangenix, Realigns Services Business

By Cormac Sheridan
Staff Writer

Tuesday, January 15, 2013
Although Galapagos NV is best known for its whopper of an alliance with AbbVie Inc. for its JAK inhibitor, GLPG0634, the company's rapidly growing drug discovery services business is set to expand further in 2013, following the acquisition of Cangenix Ltd.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription